[go: up one dir, main page]

PL3720879T3 - Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu - Google Patents

Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu

Info

Publication number
PL3720879T3
PL3720879T3 PL18829742.8T PL18829742T PL3720879T3 PL 3720879 T3 PL3720879 T3 PL 3720879T3 PL 18829742 T PL18829742 T PL 18829742T PL 3720879 T3 PL3720879 T3 PL 3720879T3
Authority
PL
Poland
Prior art keywords
immunotherapy
combination therapy
treat cancer
progastrin antibody
progastrin
Prior art date
Application number
PL18829742.8T
Other languages
English (en)
Inventor
Alexandre PRIEUR
Original Assignee
Progastrine Et Cancers S.À R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S.À R.L. filed Critical Progastrine Et Cancers S.À R.L.
Publication of PL3720879T3 publication Critical patent/PL3720879T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18829742.8T 2017-12-05 2018-12-05 Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu PL3720879T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594755P 2017-12-05 2017-12-05
PCT/EP2018/083651 WO2019110662A1 (en) 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Publications (1)

Publication Number Publication Date
PL3720879T3 true PL3720879T3 (pl) 2022-09-12

Family

ID=64949216

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18829742.8T PL3720879T3 (pl) 2017-12-05 2018-12-05 Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu

Country Status (14)

Country Link
US (2) US11046758B2 (pl)
EP (1) EP3720879B1 (pl)
JP (1) JP7104153B2 (pl)
KR (1) KR102461238B1 (pl)
CN (1) CN111670197A (pl)
AU (1) AU2018379320B2 (pl)
CA (1) CA3084687C (pl)
DK (1) DK3720879T3 (pl)
ES (1) ES2920283T3 (pl)
PL (1) PL3720879T3 (pl)
PT (1) PT3720879T (pl)
SG (1) SG11202005296SA (pl)
TW (1) TWI763956B (pl)
WO (1) WO2019110662A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102461238B1 (ko) * 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
CN112368579B (zh) * 2018-02-27 2024-05-03 Ecs前胃泌素股份有限公司 作为生物标记物的前胃泌素用于免疫疗法
CN111171146B (zh) * 2020-02-20 2022-03-04 西北农林科技大学 抗h9n2亚型禽流感病毒的纳米抗体、制备方法和应用
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5546806A (en) 1991-10-17 1996-08-20 Kain; Aron Z. Microwave vector displacement and acceleration transducer
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE60236182D1 (de) 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
WO2009054985A1 (en) 2007-10-25 2009-04-30 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
UA106771C2 (uk) * 2009-10-16 2014-10-10 Ле Лаборатуар Сервьє Моноклональні антитіла до прогастрину та їх використання
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
ES2754774T3 (es) * 2010-03-24 2020-04-20 Progastrine Et Cancers S A R L Profilaxis de cáncer colorrectal y gastrointestinal
AU2011284908B2 (en) * 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016069727A1 (en) * 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
EA037027B1 (ru) * 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело
BR112018013272A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer esofágico
CN108780091A (zh) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
CN110945025B (zh) * 2017-03-30 2023-11-03 Ecs前胃泌素股份有限公司 用于检测前列腺癌的组合物和方法
CA3058270C (en) * 2017-03-30 2023-07-18 Ecs-Progastrin Sa Compositions and methods for detecting lung cancer
EP3624841A4 (en) * 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
KR102461238B1 (ko) * 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
CN112368579B (zh) * 2018-02-27 2024-05-03 Ecs前胃泌素股份有限公司 作为生物标记物的前胃泌素用于免疫疗法

Also Published As

Publication number Publication date
DK3720879T3 (da) 2022-06-20
AU2018379320A1 (en) 2020-07-02
CA3084687C (en) 2024-01-02
KR20200118409A (ko) 2020-10-15
US20210324069A1 (en) 2021-10-21
US12180275B2 (en) 2024-12-31
EP3720879A1 (en) 2020-10-14
ES2920283T3 (es) 2022-08-02
TW201927805A (zh) 2019-07-16
CN111670197A (zh) 2020-09-15
RU2020121176A3 (pl) 2022-04-27
JP2021505576A (ja) 2021-02-18
TWI763956B (zh) 2022-05-11
PT3720879T (pt) 2022-07-13
EP3720879B1 (en) 2022-05-11
SG11202005296SA (en) 2020-07-29
JP7104153B2 (ja) 2022-07-20
WO2019110662A1 (en) 2019-06-13
US11046758B2 (en) 2021-06-29
AU2018379320B2 (en) 2023-06-15
CA3084687A1 (en) 2019-06-13
RU2020121176A (ru) 2022-01-10
KR102461238B1 (ko) 2022-11-01
US20210009680A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
PT3455259T (pt) Combinação de anticorpos anti-pd-1 e radiação para tratar o cancro
LT3331900T (lt) Peptidai ir peptidų derinys, skirti naudoti imunoterapijai gydant prostatos vėžį ir kitų rūšių vėžį
IL247066A0 (en) Cancer immunotherapy by combining local and systemic immune stimulation
IL248455B (en) igf-1r antibody-drug conjugate and its use for cancer treatment
IL254103A0 (en) Compositions and methods for increasing the effectiveness of cancer treatment
IL275517A (en) Combined methods and treatment of cancer
GEP20217317B (en) Combination therapy for the treatment of cancer
IL248704A0 (en) Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
SI3630112T1 (sl) Kombinacija regorafeniba in nivolumaba za zdravljenje raka
IL275913A (en) Methods and combined treatment for cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
IL274866A (en) Preparations and methods for the treatment of cancer
HK40053388B (en) Claudin6 antibodies and methods of treating cancer
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer
HK1232771A1 (en) Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers